Distinguished Research & Development
Scientists Prof. John H. Krystal, M.D., Jeffrey L. Cummings, M.D.
and John P. Wikswo, Jr., Ph.D. Appointed as Inaugural Members
World-renowned Psychiatrist Dr. Krystal will
Serve as Chair of the SAB
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;TSX.V:BTI),
a biopharmaceutical company focused on overcoming the limitations
of therapeutic drug delivery across the blood-brain barrier (BBB)
and into the central nervous system for the treatment of
neurological diseases and disorders, today announced the
appointments of Prof. John H. Krystal, M.D., Jeffrey L.
Cummings, M.D. and John P. Wikswo, Jr., Ph.D. to its newly
established Scientific Advisory Board (SAB). These independent
experts will serve as a strategic resource to biOasis as it
continues to advance the company’s proprietary drug delivery
platform. Dr. Krystal will serve as chairman of the SAB.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170907006012/en/
John P. Wikswo, Jr., Ph.D., Gordon A.
Cain University Professor at Vanderbilt University, Founding
Director of the Vanderbilt Institute for Integrative Biosystems
Research and Education (Photo: Business Wire)
“I’m excited to serve as chair of the biOasis SAB and to work
with Mark again,” said Dr. Krystal. “Most drugs created to treat
central nervous system diseases and disorders fail because they
aren't optimally designed to be delivered in sufficient quantities
to the brain. I look forward to working with Mark and his team to
untap the potential of the biOasis platform in the development of
differentiated treatments for previously untreatable neurological
diseases and disorders.”
Additional members will be added once their institutions approve
their membership to the biOasis SAB. The SAB will be comprised of
leaders from the academic, pharmaceutical and biotechnology
industries from discovery, translational medicine and clinical
development areas The SAB will work closely with the biOasis
management team to advance the development of the Company’s
proprietary BBB drug delivery platform, xB3. The role of the SAB is
to provide strategic guidance and direction for the biOasis
in-house development programs as well as strategic research
alliances. The SAB will also play a role in guiding and
prioritizing the company’s research investment.
“I am intrigued by the proprietary xB3 BBB drug delivery
technology that biOasis has developed and I am eager to assist with
the strategy for its development,” said Dr. Cummings.
"I am excited at the opportunity of working with biOasis and
their SAB. This is translational science at its best -- my academic
research group received five years of funding from NIH/NCATS to
develop a neurovascular unit on a chip and the supporting hardware.
We learned a lot from our experiments, colleagues, pharma, and
organ-on-chip companies, and are proceeding to develop on-chip
disease models. Now I can help guide the development of a specific
therapeutic platform," said Dr. Wikswo.
“We are honored to welcome Dr. Krystal, Dr. Cummings and Dr.
Wikswo to the new biOasis SAB. Having worked with Professors
Krystal and Cummings previously, I’ve been fortunate to have had
their guidance and support on several key studies. They helped
guide my translational research during one of the most productive
periods in my career. I can’t wait to work with them again. Dr.
Wikswo adds significant BBB experience to our board. His work
developing a BBB on a chip as part of his organs-on-a-chip program
has been extraordinary and I look forward to working with him as
well. They are all true leaders in their fields," said Mark Day,
Ph.D., president and chief executive officer, biOasis Technologies,
Inc. “Our new SAB members will provide a tremendous knowledge base
that will help to inform our approach to our ongoing research and
clinical development activities. Their collective knowledge and
guidance will be invaluable as we advance our in-house research
programs and external research alliances."
Professor John H. Krystal, M.D. is the Robert L. McNeil,
Jr., professor of translational research, chair of the department
of psychiatry, and professor of neuroscience at the Yale University
School of Medicine and chief of psychiatry at Yale-New Haven
Hospital. Dr. Krystal has published extensively on the neurobiology
and treatment of schizophrenia, alcoholism, post-traumatic stress
disorder (PTSD) and depression. Notably, he led the discovery of
the rapid antidepressant effects of ketamine in humans. Dr. Krystal
is the director of the National Alcohol Abuse and Alcoholism
Advisory Council Center for the Translational Neuroscience of
Alcoholism and the Clinical Neuroscience Division of the VA
National Center for PTSD. Dr. Krystal is a member of the U.S.
National Academy of Medicine. Currently, he is president of the
International College of Neuropsychopharmacology, a member of the
National Institute of Mental Health National Mental Health Advisory
Council and editor of Biological Psychiatry.
Dr. Krystal received his bachelor of science degree in
behavioral sciences from the University of Chicago and his doctor
of medicine degree from Yale University School of Medicine. He
completed his residency in the Yale Psychiatry Residency Training
Program.
Jeffrey L. Cummings, M.D., is director of the Cleveland
Clinic Lou Ruvo Center for Brain Health in Las Vegas and Cleveland,
the Camille and Larry Ruvo Chair of the Neurological Institute of
Cleveland Clinic and professor of medicine (neurology) at the
Cleveland Clinic Lerner College of Medicine of Case Western Reserve
University. Dr. Cummings is principal investigator/director of the
National Institutes of Health/National Institute of General Medical
Sciences-funded Center for Neurodegeneration and Translational
Neuroscience.
Dr. Cummings is a world-renowned Alzheimer’s researcher and
leader of clinical trials. He has been recognized for his research
and leadership contributions in the field of Alzheimer’s disease
through the Henderson Award of the American Geriatrics Society
(2006), the Ronald and Nancy Reagan Research Award of the national
Alzheimer’s Association (2008), and the Lifetime Achievement Award
of the Society for Behavioral and Cognitive Neurology (2017). In
2010, he was honored by the American Association of Geriatric
Psychiatry with their Distinguished Scientist Award. He was
featured in the Gentleman’s Quarterly (June 2009) as a “Rockstar of
Science.” Dr. Cummings’ interests embrace clinical trials,
developing new therapies for brain diseases, and the interface of
neuroscience and society.
Dr. Cummings was formerly professor of neurology and psychiatry
at the University of California, Los Angeles (UCLA), director of
the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA,
and director of the Deane F. Johnson Center for Neurotherapeutics
at UCLA. He is past president of the Behavioral Neurology Society
and of the American Neuropsychiatric Association. Dr. Cummings has
authored or edited 39 books and published over 700 peer-reviewed
papers.
Dr. Cummings completed his neurology residency and a fellowship
in behavioral neurology at Boston University, Boston. His U.S.
training was followed by a research fellowship in neuropathology
and neuropsychiatry at the National Hospital for Nervous Diseases,
Queen Square, London.
John P. Wikswo, Jr., Ph.D., is the Gordon A. Cain
University professor at Vanderbilt University and is the founding
director of the Vanderbilt Institute for Integrative Biosystems
Research and Education. He has been on the Vanderbilt faculty since
1977. His research has included superconducting magnetometry, the
measurement and modeling of cardiac, neural and gastric electric
and magnetic fields and non-destructive testing of aging aircraft.
In 1980, he and his group made the first measurement of the
magnetic field of a nerve impulse.
As a tenured member of the departments of biomedical
engineering, molecular physiology and biophysics, and physics and
astronomy, he is guiding the development of microfabricated
devices, optical instruments and software for studying how living
cells interact with each other and their environment and respond to
drugs, chemical/biological agents, and other toxins, thereby
providing insights into systems biology, physiology, medicine and
toxicology.
He has over 200 publications, is a fellow of seven professional
societies, and has received 22 patents. He loves teaching and
learning, and sharing his enthusiasm for research and inventing
with high-school students, undergraduates and graduate students. He
is happiest when he is tinkering and doing plumbing, carpentry and
wiring, either on his house or the ones that he and his group are
building to grow cells and miniature human organs. His group’s work
on organ-on-chips focuses on the development of intelligent well
plates that serve as perfusion controllers, microclinical analyzers
and microformulators; developing a blood-brain barrier on a chip;
and integrating multiple organs to create a milli-homunculus from
coupled organs on chips. To learn more about the development of a
microfluidic device containing human cells which can model the
blood-brain barrier, visit:
https://www.technologynetworks.com/neuroscience/videos/blood-brain-barrier-on-a-chip-29073
Dr. Wikswo trained as a physicist and he received his bachelor
of arts degree from the University of Virginia, and his doctor of
philosophy degree from Stanford University.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company focused
on overcoming the limitations of therapeutic drug delivery across
the blood-brain barrier (BBB). The delivery of therapeutics across
the BBB represents the single greatest challenge in treating
neurological disorders. The company is developing and
commercializing a proprietary brain delivery technology to address
unmet medical needs in the treatment of central nervous system
diseases and disorders. The company maintains headquarters in
Vancouver, Canada with offices in Connecticut, United States.
biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX
Venture Exchange under the symbol “BTI.” For more information about
the company please visit www.bioasis.ca.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect” and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching
our products may be greater than anticipated; we have no experience
in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
On Behalf of the Board of DirectorsMark Day, Ph.D.President
& Chief Executive OfficerbiOasis Technologies, Inc.
“Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release”
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907006012/en/
biOasis Technologies Inc.Catherine London,
+1-917-763-2709Catherine@bioasis.usorGraeme Dick,
+1-403-561-8989info@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Sep 2023 to Sep 2024